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Abstract
Background: Small-cell lung cancer (SCLC) is known to express antigens of both the neural crest and epithelium,
and to secrete polypeptide hormones and enzymes. Anecdotal reports correlate lung cancer with marked
hyperamylasemia, and a review of the literature reveals only one case of metastatic SCLC linked to high
paraneoplastic lipase production.
Case presentation: We present the case of a patient with metastatic SCLC who showed both lipase and pancreatic
isoamylase elevation in the absence of acute pancreatitis.
Chemotherapy resulted in a rapid reduction in serum lipase and in pancreatic isoamylase which was correlated with the
radiological response of the tumor to therapy. Lipase and pancreatic isoamylase expression in tumor cells from the lung
biopsy was confirmed by immunohistochemical staining.
Conclusions: This is a very rare case of paraneoplastic syndrome linked to metastatic SCLC. The enzymes secreted could
be used as markers of response to treatment until clonal selection mechanisms and intratumor heterogeneity induce
changes in biochemical characteristics and consequently in tumor behavior.
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Background
Small-cell lung cancer (SCLC) is known to express anti-
gens of both the neural crest and epithelium, and to secrete
polypeptide hormones and enzymes. The most common
paraneoplastic endocrine manifestations in SCLC are the
syndrome of inappropriate antidiuretic hormone secretion
(SIADH) and Cushing’s syndrome [1, 2]. Anecdotal reports
correlate lung cancer with marked hyperamylasemia, and a
review of the literature shows only one case of metastatic
SCLC linked to high paraneoplastic lipase production [3].
We present the case of a patient with metastatic SCLC
who showed both lipase and pancreatic isoamylase eleva-
tion in the absence of acute pancreatitis. Chemotherapy in-
duced a rapid decrease in serum lipase and in pancreatic
isoamylase which was correlated with radiological confirm-
ation of response of the tumor to therapy.
Case presentation
A 54-year-old man presented with small cell lung cancer
(SCLC) and metastases of the brain, liver, adrenal glands
and mediastinal lymph nodes. Immunohistochemically,
tumor cells were positive for CD56 and TTF1. The pa-
tient had a 30-year history of cigarette smoking and his
past medical history was significant for arterial hyperten-
sion and diabetes. He only took medications for back
pain and did not drink alcohol. Given his performance
status, we considered first-line chemotherapy with cis-
platin and etoposide. A blood test before the start of
chemotherapy showed normal renal and liver functions
but high serum lipase levels (1343 U/L, normal value
13–60 U/L). Further tests revealed elevated levels of
neuron-specific enolase (NSE) (173.9 μg/L), carcinoem-
bryonic antigen (220.7; normal value < 5 μg/L) and
serum amylase (379; normal value 1–100 U/L). Although
progastrin-releasing peptide was recently identified as a
biomarker of SCLC, we chose not to analyze it as it has
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not yet been introduced into clinical practice. Pancreatic
isoamylase value was 339 U/L (normal value 17–115 U/L).
Serum calcium and other electrolytes were normal. The
patient was asymptomatic. Magnetic resonance imaging
(MRI) of the abdomen performed to exclude pancreatic
lesions and/or pancreatitis was negative (Fig. 1).
In the absence of clinical and radiological findings of
pancreatitis, chemotherapy was begun with cisplatin and
etoposide. After the first cycle of chemotherapy, serum
lipase values decreased sharply to 592 U/L and NSE
levels fell to 24 μg/L. At the end of the third cycle, a
further reduction in serum lipase (270 U/L), pancreatic
isoamylase (128 U/L) and NSE levels (21.6 μg/L) was ob-
served and was correlated with the radiological response
of the tumor to therapy. The restaging CT scan showed
a significant reduction in the number and size of both
primary and metastatic lesions.
Given the patient’s positive response to treatment and
his good performance status, we decided to continue
chemotherapy, obtaining a normalization of the serum
lipase concentration (12 U/L vs. initial baseline level of
1343 U/L) after the sixth cycle. In addition, total serum
amylase dropped to 74 U/L, NSE to 15.7 μg/L and CEA
levels to 20.1 μg/L (Fig. 2). A second restaging CT scan
of the chest and abdomen showed a further reduction in
the size of the target lesions. However, a brain MRI
revealed disease progression with multiple lesions and
panencephalic brain radiotherapy was started. One
month after the end of chemotherapy the patient was
hospitalized due to the onset of epileptic seizures and
progressive physical decline. Palliative care was begun
but the patient died 1 week after admission (7 months
after diagnosis).
Conclusion
SCLC is believed to arise from Kulchitsky cells which
originate in the neural crest and are present beneath the
epithelial lining of the lungs. It is also reported to have
antigenic markers of both the neural crest and epithe-
lium and to secrete polypeptide hormones and enzymes
[1]. Cushing’s disease, which is related to ectopic adre-
nocorticotropic hormone secretion, and the syndrome of
inappropriate antidiuretic hormone secretion are the
most frequent paraneoplastic endocrine complications in
SCLC. There is anecdotal evidence of a correlation be-
tween lung cancer and marked hyperamylasemia. In fact,
amylase-producing tumors of the lung include adenocar-
cinoma and undifferentiated small-cell carcinoma [2].
A review of the literature revealed only one case of
metastatic SCLC with elevated paraneoplastic lipase
production which was associated with SIADH, a second
paraneoplastic condition [3, 4]. Our patient showed
both lipase and pancreatic isoamylase elevation in the
absence of acute pancreatitis or other non cancer-
related disorders.
Pancreatic amylase and lipase activity have been
found in some human non-pancreatic organs such as
the salivary glands, stomach, duodenum, large pancre-
atic ducts, extra-hepatic bile ducts and gallbladder. Ele-
vation of amylase and lipase is seen in nonmalignant
disorders such as acute pancreatitis, trauma, pancreatic
abscess, cholecystitis, common bile duct obstruction,
cholangitis and perforation or intestinal obstruction. A
rare case of nonmalignant pancreatic hyperenzymemia
was also reported by Gullo [4]. The syndrome, named
after the researcher (Gullo’s syndrome), is characterized
by a fluctuating increase in pancreatic enzyme serum
levels in the absence of pancreatic diseases.
In pathologic tissue, immunoreactivity for one or more
pancreatic enzymes is found in the epithelial cells of sal-
ivary gland pleomorphic adenoma, squamous cell carcin-
oma of the esophagus, adenocarcinoma of pancreatic
and biliary origin, and colorectal and gastric adenoma
and adenocarcinoma. Terada et al. suggested that some
tumors continue to express these enzymes after neoplas-
tic transformation [5, 6]. Isolated reports of hyperamyla-
semia in lung cancer would appear to be due to an
increase in a salivary-like amylase isoenzyme [4].
As far as we know, this is the first report of a case of ele-
vated lipase production associated with increased pancre-
atic isoamylase expression. There is strong evidence that
both hyperlipasemia and pancreatic-type hyperamylasemia
represent a paraneoplastic phenomenon. In our patient,
diagnostic tests and the absence of clinical symptoms
excluded inflammatory conditions or pancreatic disor-
ders. The rapid decrease in enzyme levels shortly after
the start of chemotherapy appeared to be closely re-
lated to the reduction in size and number of primary
Fig. 1 MRI was negative for acute pancreatitis and other diseases
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and metastatic lesions. Lipase and pancreatic isoamy-
lase expression was confirmed by immunohistochemis-
try and the percentage of immunopositive tumor cells
was evaluated with respect to the total number of
tumor cells of the biopsy. Staining intensity was scored
from 0 to 3+. In particular, histological sections of the
primary tumor showed 90 % (intensity 1+/2+) (Fig. 3a)
and 100 % (intensity 3+) (Fig. 3b) immunopositivity for
amylase and lipase, respectively. Both enzymes showed
marker-like behavior as their expression paralleled the
response of the primary tumor to chemotherapy.
In conclusion, this is a very rare case of paraneoplas-
tic syndrome linked to metastatic SCLC. The enzymes
secreted could be considered for use as markers of re-
sponse to treatment until clonal selection mechanisms
and intratumor heterogeneity induce changes in bio-
chemical characteristics and consequently in tumor
behavior.
Consent
Written informed consent for publication of their clin-
ical details and clinical images was obtained from the
patient relative of the patient. A copy of the consent
form is available for review by the Editor of this
journal.
Fig. 2 Marker trends
Fig. 3 Histological sections of the primary tumor showing 90 % (intensity 1+/2+) (a) and 100 % (intensity 3+) (b) amylase and lipase immunopositivity
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